Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Depreciation and Depletion (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Depreciation and Depletion for 3 consecutive years, with $100000.0 as the latest value for Q3 2025.

  • Quarterly Depreciation and Depletion fell 50.0% to $100000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $300000.0 through Dec 2025, down 50.0% year-over-year, with the annual reading at $300000.0 for FY2025, 50.0% down from the prior year.
  • Depreciation and Depletion hit $100000.0 in Q3 2025 for Compass Therapeutics, roughly flat from $100000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $200000.0 in Q1 2023 to a low of $100000.0 in Q3 2023.
  • Historically, Depreciation and Depletion has averaged $145454.5 across 3 years, with a median of $100000.0 in 2023.
  • Biggest YoY gain for Depreciation and Depletion was 100.0% in 2024; the steepest drop was 50.0% in 2024.
  • Year by year, Depreciation and Depletion stood at $200000.0 in 2023, then plummeted by 50.0% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025.
  • Business Quant data shows Depreciation and Depletion for CMPX at $100000.0 in Q3 2025, $100000.0 in Q2 2025, and $100000.0 in Q1 2025.